Dr. Robinson, is Professor of Medicine, was the first head of the Division of Medical Oncology, and currently holds the Monroe and Rella Rifkin Endowed Chair at the University of Colorado. Dr. Robinson co-discovered the FDA-approved version of MNGX-100 in the 1960's and is a research and clinical leader in the fields of hematopoiesis and melanoma.

Ms. Duke has an extensive entrepreneurial background including staffing and recruiting for the oil & gas, renewable energy, biotech and pharmaceutical industry both as a principal in recruiting firms and at the National Renewable Energy Laboratory. She has also served as President of Duke Medical Research Group, a consulting firm with ~80 life science professionals that provided third party independent research to the mutual fund industry.

Dr. Santoro is Professor of Medicine and the E. Stewart Taylor Chair of Obstetrics and Gynecology at the University of Colorado. She came to Colorado from the Albert Einstein College of Medicine. Her major research interests include the reproductive endocrinology of premature, peri-, and post-menopause, infertility, and the physiology of gonadotropin-releasing hormone secretion.

Dr. Wierman is Professor in Medicine, Physiology and Biophysics at the University of Colorado and Chief of Endocrinology at the Denver VAMC. Dr. Wierman is a clinical neuroendocrinologist and reproductive endocrinologist. Her research interests are in the genes and hormones of the reproductive axis with studies on sex hormone regulation, development control of GnRH and understanding the pathogenesis of gonadotrope pituitary tumors.

Dr. Duke is a biotechnology executive, inventor, biomedical researcher and serial entrepreneur with nearly 20 years of experience in building, financing, and managing start-up biotechnology companies. He is currently CSO of the Colorado Institute for Drug, Device and Diagnostic Development and has been involved in the formation and active management of 6 biotech companies: GlobeImmune; Newellink; ApopLogic; Sierra Neuro; MenoGeniX and PeptiVir.

Mr. Rona began his career as an investment banker and has served in the role of Chief Business Officer and Chief Financial Officer in three biotechnology companies: Antigenics; AlgoRx and GlobeImmune. He has raised nearly $0.5 billion in financing in the course of his career.

Mr. Frank has over 30 years exeprience as a biotech executive (Genentech, Pharmatec, CV Theraputics), investor (Life Science Angels), philanthoprist and advisor (Stanford and UCSF)